Inflammatory Alveolar Type 2 Cells in Chronic Obstructive Pulmonary Disease: Impairing or Improving Disease Outcome?

Pavan Prabhala,Mattias Magnusson

DOI: https://doi.org/10.1165/rcmb.2022-0371ED

IF: 7.748

2022-12-02

American Journal of Respiratory Cell and Molecular Biology

Abstract:Chronic obstructive pulmonary disease (COPD) is characterized by aberrant inflammatory and repair responses, leading to bronchitis, small airway remodeling, and emphysema. It is the third leading cause of death worldwide and is caused by exposure to tobacco smoke or environmental pollutants (1). Importantly, the inflammatory processes in COPD are known to persist long after smoking cessation (2). However, the underlying mechanisms that initiate and drive inflammation are still not clear, and currently, no pharmacological treatments are available to alter the course of the disease. These mechanisms include defective epithelial repair in the airways and alveoli, suggesting that the endogenous lung stem cells may be the initial drivers of the disease. In line with that, research has demonstrated that basal (stem) cells in the airway are among the first cells to be affected by inhaled toxins, resulting in epithelial damage, defective repair, and subsequent inflammation (3, 4). The mechanisms triggering the initiation of this inflammation are not understood, but it is clear that the epithelial cells are in constant communication with the inflammatory cells. It was recently shown that a subpopulation of basal cells can drive the inflammatory processes observed in COPD, suggesting that these inflammatory signals represent a potential therapeutic target to inhibit tissue destruction and promote regeneration of the normal cells that still exist in the airways at end-stage COPD (5, 6). In the alveolar compartment, the alveolar type 2 (AT2) cells are the stem cells responsible for homeostasis and regeneration ( Figure 1A ). Even though AT2 cells have been evaluated in multiple single-cell OMICS studies (7–9), the mechanistic alterations in AT2 cells in COPD are unknown, and the question remains as to whether a disease-propagating subpopulation of AT2 cells exists in COPD. Hence, a deeper understanding of the AT2 cells in patients with COPD is needed to understand their contribution to disease.